Pavel O. Bogomolov

Pavel O. Bogomolov

Auto-generated profile, based on publicly available information

Pavel O. Bogomolov

Moscow Regional Research and Clinical Institute (MONIKI)

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2025 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ODOxana M. Drapkina
Oxana M. Drapkina
MMM. V. Maevskaya
M. V. Maevskaya
KRK. L. Raikhelson
K. L. Raikhelson
SOSergey Okovityi
Sergey Okovityi
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.

24 January 2025 in Liver International
Verified
Journal Article
Open access
PLPietro Lampertico
Pietro Lampertico
PBPavel O. Bogomolov
Pavel O. Bogomolov
VCVladimir Chulanov
Vladimir Chulanov
TSTatiana Stepanova
Tatiana Stepanova
VMViacheslav Morozov
Viacheslav Morozov
HWHeiner Wedemeyer
Heiner Wedemeyer
Background and Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up.Methods: Ninety patients were enrolled into six arms of 15 each (A–F); 60 patients were included in the main randomisation (arms A–D), and 30 patients (arms E–F) were randomised to the extension phase: (A) Peg‐IFNα‐2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg‐IFNα‐2a 180 μg QW; (C) BLV 5 mg QD + Peg‐IFNα‐2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg‐IFNα‐2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD. The primary endpoint was undetectable HDV RNA at week (W)72.Results: At W72, 53%, 27%, 7%, 7% and 33% of patients achieved undetectable HDV RNA in arms B, C, D, E and F, respectively, versus 0% in arm A. More arm B versus A patients had a > 1 log10 IU/mL decline in or loss of hepatitis B surface antigen (HBsAg) at W72 (p = 0.017), including four patients with loss of HBsAg. Bile acid elevations were dose‐dependent and reversible following the completion of BLV treatment.Conclusions: BLV combined with Peg‐IFNα‐2a was well tolerated and resulted in high rates of HDV RNA undetectability off‐treatment.Trial Registration: NCT02888106

13 December 2017 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
EMEkaterina E. Mishina
Ekaterina E. Mishina
AMAlexander Y. Mayorov
Alexander Y. Mayorov
PBPavel O. Bogomolov
Pavel O. Bogomolov
MMMaria V. Matsievich
Maria V. Matsievich
KKKsenia Y. Kokina
Ksenia Y. Kokina
БВБоголюбова Аполлинария Васильевна
Боголюбова Аполлинария Васильевна
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are pathological conditions that are co-occurring, and have been reaching epidemic proportions. One of the most significant risk factors for the development of both T2DM and NAFLD is obesity, which increases existing insulin resistance (IR). IR thought to be one of the main pathogenic causes linking T2DM and NAFLD. In recent years, there has been increased interest in obtaining non-invasive methods for assessing fibrosis and determining indications for liver biopsy, such as the NAFLD fibrosis score, extended liver fibrosis panel, and transient elastography. However, liver biopsy remains the gold standard for diagnosing NAFLD. Given that patients with T2DM are at higher risk of NAFLD than the general population, and that the presence of diabetes is a risk factor for the progression of NAFLD, patients with T2DM should be more closely monitored by clinicians. The present review paper is devoted to the search for causeeffect relationships of concurrent diseases such as NAFLD and disorders of carbohydrate metabolism, and priority areas of diagnosis of NAFLD.

11 August 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
MCMaria Caldas
Maria Caldas
AAANGELES Perez Aisa
ANGELES Perez Aisa
BTBojan Tepeš
Bojan Tepeš
AKAlma Keco-Huerga
Alma Keco-Huerga
Luis BujandaLuis Bujanda
Luis Bujanda
Dmitry S BordinDmitry S Bordin
Dmitry S Bordin
Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1–1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59–0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4–2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3–5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.

4 June 2023 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
NMN. A. Mamonova
N. A. Mamonova
MMM. V. Maevskaya
M. V. Maevskaya
ZMZharkova Maria
Zharkova Maria
NYN. D. Yushchuk
N. D. Yushchuk
Аim:diagnosis and treatment algorithms in the clinical recommendations intended for general practitioners, gastroenterologists, infectious disease specialists, hepatologists on the of chronic hepatitis C are presented.Summary.Chronic viral hepatitis C is a socially significant infection, the incidence of which in the Russian Federation remains significantly high. Over the past 10 years, great progress has been made in the treatment of hepatitis C — direct acting antiviral drugs have appeared. The spectrum of their effectiveness allows to achieve a sustained virological response in more than 90 % of cases, even in groups that were not previously considered even as candidates for therapy or were difficult to treat — patients receiving renal replacement therapy, after liver transplantation (or other organs), at the stage of decompensated liver cirrhosis, HIV co-infected, etc. Interferons are excluded from the recommendations due to their low effectiveness and a wide range of adverse events. The indications for the treatment have been expanded, namely, the fact of confirmation of viral replication. The terms of dispensary observation of patients without cirrhosis of the liver have been reduced (up to 12 weeks after the end of therapy). Also, these recommendations present approaches to active screening of hepatitis in risk groups, preventive and rehabilitation measures after the end of treatment.Conclusion.Great success has been achieved in the treatment of chronic hepatitis C. In most cases, eradication of viral HCV infection is a real task even in patients at the stage of cirrhosis of the liver, with impaired renal function, HIV co-infection, after solid organs transplantation.

31 January 2019 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
PBPavel O. Bogomolov
Pavel O. Bogomolov
KKKseniya Yu. Kokina
Kseniya Yu. Kokina
AMAleksander Yu. Mayorov
Aleksander Yu. Mayorov
EMEkaterina E. Mishina
Ekaterina E. Mishina
АМА. Ю. Майоров
А. Ю. Майоров
Non-alcoholic fatty liver disease (NAFLD) is the most commonly diagnosed hepatopathy. There is an increase in the incidence of NAFLD in the structure of liver diseases in children and adolescents, which is directly related to the increasing prevalence of obesity. The spectrum of liver tissue changes in NAFLD ranges from benign hepatocellular steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis of the liver, and hepatocellular carcinoma. With the increasing prevalence of NAFLD in children, we can expect an increase in the incidence of adverse outcomes among people of working age. The key problem for NAFLD is the prediction of disease outcomes. In epidemiological and genetic studies, the relationship between the morphological stage of NAFLD and hereditary factors is shown. Currently, there are three genes associated with NAFLD (PNPLA3, TM6SF2, and GCKR), which, together with the genes responsible for insulin resistance, lipid deposition, inflammation and fibrogenesis in hepatocytes, determine the phenotype of fatty liver disease. The article considers the modern understanding of the issues of genetics, development of liver steatosis and progression of NASH. It is expected that this knowledge can transform our risk stratification strategies in patients with NAFLD and help identify new therapeutic goals.